NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1292.30 -26.70 (-2.02%)

26.70% Gain from 52W Low

1.6M NSE+BSE Volume

NSE 13 Mar, 2026 3:31 PM (IST)

107,862.2

Market Cap

High in industry

Beta 1Year

Low volatility

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

23 Feb 2026

1292.30

-2.02%

DR. REDDY'S LABORATARIES

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The North American business faced challenges, with revenue declining due to decreased Lenalidomide sales and increased price erosion for certain key products. Additionally, the delayed launch of biosimilars limited revenue growth during the quarter. However, Q3FY26 witnessed strong performance in India, Emerging markets, and the newly acquired consumer healthcare unit, which is focused on nicotine replacement therapy. The company aims to boost core business growth, advance patented products such as Semaglutide and Abatacept, improve operational...

Dr. Reddy's Laborato.. has an average target of 1314.44 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

23 Jan 2026

1292.30

-2.02%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Direct

About the stock: Dr Reddy's (DRL) business encompasses generic formulations sales across US, Europe, RoW markets and branded generics in India and Russia CIS. The business also comprises of API sales under the head PSAI. The company...

Geojit BNP Paribas upgraded Dr. Reddy's Laboratories Ltd. to Hold with a price target of 1390.0 on 23 Feb, 2026.

Dr. Reddy's Laboratories Ltd.

22 Jan 2026

1292.30

-2.02%

Dr Reddy's Labs (BUY): ex of North America, guidance above expectations

Buy: Dr. Reddy's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 1.4%/0.1%-7.1%. EBITDA margin in-line, marginally 28bps below our estimates

Geojit BNP Paribas upgraded Dr. Reddy's Laboratories Ltd. to Hold with a price target of 1390.0 on 23 Feb, 2026.

Dr. Reddy's Laboratories Ltd.

12 Dec 2025

1292.30

-2.02%

Growth levers in place, but near-term earnings drag limits upside

Neutral: Dr. Reddy's Laboratories Ltd.

Motilal Oswal

While increased competition in g-Revlmid would weigh on DRRD’s near-term performance, the company is implementing efforts to improve growth prospects over the next 2-3 years.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

29 Oct 2025

1292.30

-2.02%

A muted quarter as robust growth across non-US markets was offset by US pricing pressure.

Sell: Dr. Reddy's Laboratories Ltd.

Target

Deven Choksey

Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1292.30

-2.02%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our HOLD recommendation on the stock.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1292.30

-2.02%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Direct

Number of FII/FPI investors decreased from 872 to 855 in Dec 2025 qtr

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1292.30

-2.02%

Dr Reddy's Labs (HOLD): Margins depict price erosion in Revlimid; Europe to shine

Hold: Dr. Reddy's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/ EBITDA/PAT reported 1.7%/-5%/-1.1% above our estimates; 0.4%/-7.2%/1.2% above consensus estimates

Geojit BNP Paribas upgraded Dr. Reddy's Laboratories Ltd. to Hold with a price target of 1390.0 on 23 Feb, 2026.

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1292.30

-2.02%

GM weakness persists; pipeline uncertainty heightens

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

The 2QFY26 margin performance of Dr Reddy’s was marginally weaker than our expectations (in line with street estimates; adjusted for one-offs), with the gross margin (GM) decline being sharper than our expectations (at 55%, GM logged at its lowest since the launch of gRevlimid) and largely a consequence of lower-than-expected gRevlimid sales.

Dr. Reddy's Laborato.. has an average target of 1314.44 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1292.30

-2.02%

Launches critical to revive growth

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Dr. Reddy’s Laboratories’ (DRL) Q2FY26 revenue was slightly ahead of our expectations, though EBITDA and profit were in line. Revenue growth of 9.8% YoY was boosted by consolidation (65-70%) of the acquired NRT portfolio (~8% of sales) and acquisition of other branded products.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Is Dr. Reddy's Laboratories Ltd. worth buying?

544 Votes:

Buy 77.76%

Sell 12.68%

Hold 9.56%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf